Total Payments
$219,082
2024 Payments
$1,999
Companies
33
Transactions
342
Medicare Patients
11,597
Medicare Billing
$4.0M
Payment Breakdown by Category
Other$190,305 (86.9%)
Travel$12,899 (5.9%)
Consulting$10,395 (4.7%)
Food & Beverage$5,468 (2.5%)
Education$15.63 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $189,140 | 68 | 86.3% |
| Travel and Lodging | $12,899 | 66 | 5.9% |
| Consulting Fee | $10,395 | 12 | 4.7% |
| Food and Beverage | $5,468 | 182 | 2.5% |
| Long term medical supply or device loan | $1,165 | 13 | 0.5% |
| Education | $15.63 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $55,023 | 89 | $0 (2024) |
| Merck Sharp & Dohme LLC | $43,610 | 68 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $41,571 | 41 | $0 (2024) |
| ARRAY BIOPHARMA INC | $37,249 | 31 | $0 (2024) |
| Amgen Inc. | $17,833 | 27 | $0 (2018) |
| GENZYME CORPORATION | $13,070 | 10 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $4,943 | 5 | $0 (2023) |
| PFIZER INC. | $3,675 | 12 | $0 (2024) |
| Celgene Corporation | $1,026 | 10 | $0 (2023) |
| Galt Pharmaceuticals, LLC | $128.37 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,999 | 64 | Novartis Pharmaceuticals Corporation ($1,282) |
| 2023 | $957.64 | 38 | Novartis Pharmaceuticals Corporation ($276.82) |
| 2022 | $1,955 | 45 | Celgene Corporation ($974.71) |
| 2021 | $877.20 | 3 | GENZYME CORPORATION ($822.00) |
| 2020 | $4,475 | 3 | PFIZER INC. ($3,400) |
| 2019 | $130,575 | 103 | Array BioPharma Inc. ($37,178) |
| 2018 | $48,500 | 58 | Novartis Pharmaceuticals Corporation ($16,169) |
| 2017 | $29,742 | 28 | E.R. Squibb & Sons, L.L.C. ($12,976) |
All Payment Transactions
342 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $16.44 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $28.72 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $9.63 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.08 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 10/07/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $7.67 | General |
| Category: Immunology | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 09/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $13.33 | General |
| Category: Oncology | ||||||
| 09/04/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: Oncology | ||||||
| 09/04/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $0.37 | General |
| Category: Oncology | ||||||
| 08/28/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: ONCOLOGY | ||||||
| 08/23/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 08/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $25.61 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: Oncology | ||||||
| 07/26/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: Oncology | ||||||
| 07/23/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $3.60 | General |
| Category: Immunology | ||||||
| 07/23/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $2.29 | General |
| Category: Immunology | ||||||
| 07/19/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $20.82 | General |
| Category: Oncology | ||||||
| 07/17/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.93 | General |
| Category: ONCOLOGY | ||||||
| 07/15/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 06/28/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $20.92 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 65 | 5,768 | 83,006 | $7.3M | $2.1M |
| 2022 | 60 | 3,940 | 47,196 | $3.9M | $1.1M |
| 2021 | 36 | 1,576 | 23,024 | $2.7M | $796,183 |
| 2020 | 4 | 313 | 473 | $143,765 | $39,567 |
Total Patients
11,597
Total Services
153,699
Medicare Billing
$4.0M
Procedure Codes
168
All Medicare Procedures & Services
168 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 20 | 20,200 | $2.8M | $874,233 | 30.9% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 11 | 14,760 | $1.9M | $557,641 | 29.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 46 | 10,800 | $702,000 | $198,487 | 28.3% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 54 | 5,900 | $442,500 | $99,191 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 359 | 738 | $147,600 | $67,687 | 45.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 72 | 460 | $184,000 | $42,510 | 23.1% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 16 | 12,615 | $126,150 | $29,997 | 23.8% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 16 | 68 | $102,000 | $22,936 | 22.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 614 | 1,789 | $76,927 | $18,411 | 23.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 607 | 1,918 | $19,180 | $16,095 | 83.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 193 | 250 | $45,000 | $16,013 | 35.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 625 | 1,984 | $69,440 | $15,002 | 21.6% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 44 | 890 | $146,850 | $14,813 | 10.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 15 | 189 | $37,800 | $9,794 | 25.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 101 | 190 | $38,000 | $8,221 | 21.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 69 | 69 | $20,700 | $8,116 | 39.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 113 | 701 | $70,100 | $7,661 | 10.9% |
| J1750 | Injection, iron dextran, 50 mg | Office | 2023 | 24 | 510 | $22,950 | $6,783 | 29.6% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 299 | 481 | $16,835 | $6,319 | 37.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 129 | 504 | $50,400 | $5,083 | 10.1% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 227 | 281 | $9,835 | $4,066 | 41.3% |
| 83550 | Iron binding capacity | Office | 2023 | 295 | 471 | $11,775 | $3,987 | 33.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 23 | 86 | $17,200 | $3,949 | 23.0% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 108 | 199 | $8,955 | $3,276 | 36.6% |
| 83883 | Nephelometry, test method using light | Office | 2023 | 62 | 239 | $7,170 | $3,186 | 44.4% |
About Dr. Robert Conry, MD
Dr. Robert Conry, MD is a Hematology & Oncology healthcare provider based in Birmingham, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548203235.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Conry, MD has received a total of $219,082 in payments from pharmaceutical and medical device companies, with $1,999 received in 2024. These payments were reported across 342 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($189,140).
As a Medicare-enrolled provider, Conry has provided services to 11,597 Medicare beneficiaries, totaling 153,699 services with total Medicare billing of $4.0M. Data is available for 4 years (2020–2023), covering 168 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Birmingham, AL
- Active Since 06/13/2006
- Last Updated 06/10/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1548203235
Products in Payments
- MEKINIST (Drug) $53,447
- KEYTRUDA (Biological) $43,490
- OPDIVO (Biological) $40,662
- Braftovi (Drug) $37,178
- IMLYGIC (Biological) $16,632
- LIBTAYO (Drug) $11,190
- LIBTAYO (Biological) $5,765
- BRAFTOVI (Drug) $3,418
- KISQALI (Drug) $1,177
- Neulasta (Biological) $800.00
- Orphengesic Forte (Drug) $128.37
- IMBRUVICA (Drug) $125.69
- XTANDI (Drug) $120.00
- REBLOZYL (Biological) $82.14
- QINLOCK (Drug) $75.30
- PLUVICTO (Drug) $72.33
- Enhertu (Drug) $56.69
- OXBRYTA (Drug) $56.34
- Lenvima (Drug) $55.28
- OPDUALAG (Drug) $54.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Birmingham
Dr. Khaleel Ashraf, M.d, M.D
Hematology & Oncology — Payments: $628,093
Hematology & Oncology $628,093
Amitkumar Mehta
Hematology & Oncology — Payments: $581,179
Hematology & Oncology $581,179
Luciano Costa
Hematology & Oncology — Payments: $447,833
Hematology & Oncology $447,833
Dr. Michael Birrer, M.d. Ph.d, M.D. PH.D
Hematology & Oncology — Payments: $432,657
Hematology & Oncology $432,657
Pankit Vachhani, Md, MD
Hematology & Oncology — Payments: $405,357
Hematology & Oncology $405,357
Dr. Mayur Narkhede, M.d, M.D
Hematology & Oncology — Payments: $205,834
Hematology & Oncology $205,834